IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer
Our study reveals previously unrecognized functions of TAP2 beyond antigen presentation and establishes a reversible multi-cellular axis mediating adaptive immune evasion and immunotherapy resistance with clinical potential.
Authors
- Barani Kumar Rajendran (ORCID: https://orcid.org/0000-0001-9675-7718)
- Miguel López de Rodas (ORCID: https://orcid.org/0000-0002-6062-4064)
- Soldano Ferrone (ORCID: https://orcid.org/0000-0003-2900-8834)
- Imad ud Deen
- Shruti Desai (ORCID: https://orcid.org/0000-0002-5234-5890)
- Kurt A. Schalper (ORCID: https://orcid.org/0000-0001-5692-4833)
- Kishu Ranjan (ORCID: https://orcid.org/0000-0003-1256-181X)
- Adrien Costantini (ORCID: https://orcid.org/0000-0002-7524-7169)
- Nicole Gianino (ORCID: https://orcid.org/0000-0003-1919-5920)
- Frankie Scallo
Institutions
- Harvard University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
Publication Details
- Journal
- Molecular Cancer
- Published
- 2025-03-17
- DOI
- https://doi.org/10.1186/s12943-025-02276-z
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 8.36
Funders
- National Institutes of Health
- Merck Sharp and Dohme
- Yale SPORE in Lung Cancer